RT Journal Article
SR Electronic
T1 Optimal Allocation of COVID-19 Vaccines in the Philippines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.12.21251640
DO 10.1101/2021.02.12.21251640
A1 Christian Alvin H. Buhat
A1 Destiny SM. Lutero
A1 Yancee H. Olave
A1 Kemuel M. Quindala III
A1 Mary Grace P. Recreo
A1 Dylan Antonio SJ. Talabis
A1 Monica C. Torres
A1 Jerrold M. Tubay
A1 Jomar F. Rabajante
YR 2021
UL http://medrxiv.org/content/early/2021/02/18/2021.02.12.21251640.abstract
AB Vaccine allocation is a national concern especially for countries such as the Philippines that have limited resources in acquiring COVID-19 vaccines. As such, certain groups are suggested to be prioritized for vaccination to protect the most vulnerable before vaccinating others. Our model suggests an allocation of vaccines such that COVID-19 deaths are minimized while the prioritization framework is satisfied. Results of the model show that a vaccine coverage of at least 50 to 70% of the population can be enough for a community with limited supplies, and an increase in vaccine supply is beneficial if initial coverage is less than the specified target range. Also, among the vaccines considered in the study, the one with 89.9% effectiveness and has a 183 Philippine peso (Php) price per dose projected the least number of deaths. Compared to other model variations and common allocation approaches, the model has achieved both an optimal and equitable allocation. This will be helpful for policymakers in determining a vaccine distribution for a resource-constrained community.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is funded by the University of the Philippines Resilience Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB not applicable since this is a mathematical model only.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request to the authors.